Skip to Content

Dobutamine Disease Interactions

There are 5 disease interactions with dobutamine:

Major

Dobutamine (applies to dobutamine) asthmatics

Major Potential Hazard, Moderate plausibility.

Dobutamine injection contains sodium metabisulfite, a sulfite that may cause anaphylactic symptoms and life-threatening or less severe asthmatic episodes in susceptible people, such as asthmatic patients.

Major

Dobutamine/arbutamine (applies to dobutamine) arrhythmias

Major Potential Hazard, High plausibility. Applicable conditions: Hypertension

Dobutamine and arbutamine produce stimulation of the beta receptors of the heart. The use of these agents has been associated with an increase in heart rate, ventricular ectopy, atrial fibrillation, hypertension, enhanced A-V conduction, and arrhythmias. Therapy with dobutamine or arbutamine should be administered cautiously in patients with cardiac conduction disorders.

References

  1. "Product Information. Dobutrex (dobutamine)." Lilly, Eli and Company, Indianapolis, IN.
  2. Cohen A, Chauvel C, Benhalima B, Blanchard B "Complication of dobutamine stress echocardiography." Lancet 345 (1995): 201-2
  3. Poldermans D, Fioretti PM, Boersma E, Forster T, Vanurk H, Cornel JH, Arnese M, Roelandt JRTC "Safety of dobutamine-atropine stress echocardiography in patients with suspected or proven coronary artery disease." Am J Cardiol 73 (1994): 456-9
  4. Previtali M, Lanzarini L, Fetiveau R, Poli A, Diotallevi P "Dobutamine-induced and spontaneous sustained ventricular tachycardia in recent myocardial infarction." Eur Heart J 17 (1996): 803-4
  5. Tisdale JE, Patel R, Webb CR, Borzak S, Zarowitz BJ "Electrophysiologic and proarrhythmic effects of intravenous inotropic agents." Prog Cardiovasc Dis 38 (1995): 167-80
  6. Baudhuin T, Marwick T, Melin J, Wijns W, D'Hondt AM, Detry JM "Diagnosis of coronary artery disease in elderly patients: safety and efficacy of dobutamine echocardiography." Eur Heart J 14 (1993): 799-803
  7. Bianchi C, Diaz R, Gonzales C, Beregovich J "Effects of dobutamine on atrioventricular conduction." Am Heart J 90 (1975): 474-8
  8. Kinder C, Chamberlain J, Kall J, Kopp D, Johnson M, Costanzo MR, Wilber D "Prognostic significance of sustained ventricular tachyarrhythmia occurring during dobutamine infusion." J Heart Lung Transplant 13 (1994): 1045-50
  9. "Product Information. GenESA (arbutamine)." Gensia Inc, San Diego, CA.
  10. Picano E, Mathias W, Pingitore A, Bigi R, Previtali M "Safety and tolerability of dobutamine-atropine stress echocardiography: a prospective, multicentre study." Lancet 344 (1994): 1190-2
View all 10 references
Major

Dobutamine/arbutamine (applies to dobutamine) hypotension

Major Potential Hazard, High plausibility. Applicable conditions: Dehydration

The use of dobutamine and arbutamine has been infrequently associated with significant hypotension especially in dehydrated patients secondary to beta-2 mediated vasodilation. Hypovolemia should be corrected before administering dobutamine or arbutamine. Blood pressure and ECG should be monitored at regular intervals. Monitoring of cardiac output and pulmonary wedge pressure may also be desired.

References

  1. Heinle SK, Tice FD, Kisslo J "Hypotension during dobutamine stress echocardiography: is it related to dynamic intraventricular obstruction?" Am Heart J 130 (1995): 314-7
  2. "Product Information. GenESA (arbutamine)." Gensia Inc, San Diego, CA.
  3. "Product Information. Dobutrex (dobutamine)." Lilly, Eli and Company, Indianapolis, IN.
  4. Rosamond TL, Vacek JL, Hurwitz A, Rowland AJ, Beauchamp GD, Crouse LJ "Hypotension during dobutamine stress echocardiography: initial description and clinical relevance." Am Heart J 123 (1992): 403-7
View all 4 references
Major

Dobutamine/arbutamine (applies to dobutamine) IHSS

Major Potential Hazard, High plausibility. Applicable conditions: Hypertrophic Cardiomyopathy

The use of dobutamine or arbutamine is contraindicated in patients with idiopathic hypertrophic subaortic stenosis (IHSS). Dobutamine or arbutamine may increase the pressure gradient within the left ventricle and thereby worsen cardiac output in patients with IHSS.

References

  1. "Product Information. GenESA (arbutamine)." Gensia Inc, San Diego, CA.
Moderate

Dobutamine (applies to dobutamine) hypokalemia

Moderate Potential Hazard, Moderate plausibility.

The use of dobutamine has been associated with hypokalemia. Therapy with dobutamine should be administered cautiously to patients with hypokalemia. Frequent monitoring of serum potassium along with appropriate electrolyte replacement is recommended.

Dobutamine drug interactions

There are 154 drug interactions with dobutamine

Dobutamine alcohol/food interactions

There is 1 alcohol/food interaction with dobutamine

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.